Abstract:The inflammation is the protective response of the body against various harmful stimuli; however, the aberrant and inappropriate activation tends to become harmful. The acute inflammatory response tends to resolved once the offending agent is subside but this acute response becomes chronic in nature when the body is unable to successfully neutralized the noxious stimuli. This chronic inflammatory microenvironment is associated with the release of various pro-inflammatory and oncogenic mediators such as nitric oxide (NO), cytokines [IL-1β, IL-2, interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α)], growth factor, and chemokines. These mediators make the inflammatory microenvironment more vulnerable toward tumorigenesis. The pro-inflammatory mediators released during the chronic inflammation tends to induce several molecular signaling cascades such as nuclear factor kappa B, MAPKinase, nuclear factor erythroid 2-related factor 2, phosphoinositide-3-kinase, Janus kinases/STAT, Wnt/B-catenin, and cyclic AMP response element binding protein. The immune system and its components have a pleiotropic effect on inflammation and cancer progression. Immune components such as T cells, natural killer cells, macrophages, and neutrophils either inhibit or enhance tumor initiation depending on the type of tumor and immune cells involved. Tumor-associated macrophages and tumor-associated neutrophils are pro-tumorigenic cells highly prevalent in inflammation-mediated tumors. Similarly, presence of T regulatory (Treg) cells in an inflammatory and tumor setting suppresses the immune system, thus paving the way for oncogenesis. However, Treg cells also inhibit autoimmune inflammation. By contrast, cytotoxic T cells and T helper cells confer antitumor immunity and are associated with better prognosis in patients with cancer. Cytotoxic T cells inflict a direct cytotoxic effect on cells expressing oncogenic markers. Currently, several anti-inflammatory and antitumor therapies are under trials in which these immune cells are exploited. Adoptive cell transfer composed of tumor-infiltrating lymphocytes has been tried for the treatment of tumors after their ex vivo expansion. Mediators released by cells in a tumorigenic and inflammatory microenvironment cross talk with nearby cells, either promoting or inhibiting inflammation and cancer. Recently, several cytokine-based therapies are either being developed or are under trial to treat such types of manifestations. Monoclonal antibodies directed against TNF-α, VEGF, and IL-6 has shown promising results to ameliorate inflammation and cancer, while direct administration of IL-2 has been shown to cause tumor regression.

The Therapeutic Value of Targeting Inflammation in Gastrointestinal Cancers

Cancer Immunotherapies Targeting Tumor-Associated Regulatory T Cells

Targeting cancer-promoting inflammation — have anti-inflammatory therapies come of age?

Targeting Inflammation As Cancer Therapy

Targeting the Inflammatory Pathways to Enhance Chemotherapy of Cancer

Immunological Approaches Towards Cancer and Inflammation: A Cross Talk

Immunological Approaches Towards Cancer and Inflammation: A Cross Talk.

Targeting The Key Factors Of Inflammation In Cancer: Plant Intervention

Inflammatory Cytokine: An Attractive Target for Cancer Treatment

Targeting of the innate immunity/inflammation as complementary anti-tumor therapies

Inflammatory Cytokines in Cancer: Comprehensive Understanding and Clinical Progress in Gene Therapy

Inflammation and tumor progression: signaling pathways and targeted intervention

From Inflammation to Cancer: the Molecular Basis

Immunity, Inflammation, and Cancer

Inflammation-Associated Stem Cells in Gastrointestinal Cancers: Their Utility as Prognostic Biomarkers and Therapeutic Targets

Inflammation and cancer: advances and new agents

Regulation of antitumor immunity by inflammation-induced epigenetic alterations

Inflammation and cancer: friend or foe?

Tumor-related interleukins: old validated targets for new anti-cancer drug development

Chronic inflammation, cancer development and immunotherapy

Prevention and treatment of cancer targeting chronic inflammation: research progress, potential agents, clinical studies and mechanisms